Invitae Corporation

New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

by

– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care – SAN FRANCISCO, May 26, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting … Read more

Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO

by

SAN FRANCISCO, May 25, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. The Company has initiated a search for a new CFO. Ms. Wen will continue in her role through the end of the second … Read more

Invitae to Appeal Trial Verdict

by

SAN FRANCISCO, May 15, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware. The jury found that Invitae’s products using Anchored Multiplex PCR (“AMP”) chemistry infringe certain Natera, Inc. patents. … Read more